
NK Cell therapy - Pipeline Insight, 2025
Description
DelveInsight’s, “NK Cell Therapies - Pipeline Insight, 2025” report provides comprehensive insights about 140+ companies and 160+ pipeline drugs in NK Cell Therapies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
NK Cell Therapies: Overview
Natural killer cells, also known as NK cells are a type of lymphocytes and are key components of the innate immune system. They are highly specific predators that play a major role in the host rejection of both tumors and viral infected cells. NK cells have cytotoxic small granules, which contain special proteins such as perforins and proteases, are known as granzymes in their cytoplasm. Perforins form pores in the cell membrane of the target cell through which the granzymes and associated molecules induce apoptosis. NK cells are derived from the common lymphoid progenitor cells (lymphoblasts), which also generate B and T lymphocytes. They differentiate and mature in the bone marrow, lymph nodes, spleen, tonsils, and thymus, where they then enter into the bloodstream.
NK cells are capable of extravasations and infiltration into tissues and they are activated by interleukins. Natural Killer (NK) cells are capable of secreting cytokines. They act as both cytotoxic effectors and regulators of immune responses and also help in recognizing microbial infection and tumor transformation. They are developed from lymphoid progenitor cells present in the bone marrow. By recognizing self MHC class I molecules, these cells become self-tolerant. After maturation NK cells migrate to lymphoid organs including the liver, uterus, and thymus where they give rise to tissue-specific, functionally distinct mature NK cell subsets.
NK cells act on a large number of receptors that deliver either activating or inhibitory signals. The relative balance of inhibitors and activator signals controls the NK cell activity. NK cell activates post detection of abnormalities in the target cell. It may be due to loss of MHC class I expression or up-regulation of stress-induced ligands that occurs in response to infection or malignant transformation.
NK cells surveillance system includes a number of cell surface activating and inhibitory receptors that control the cytolytic activity of NK cells by sending an either stimulatory or inhibitory signal. The fine balance between activation and inhibition NK cells decides their final action. The inhibitory receptor’s ligands include self-MHC class I molecules that are present on all nucleated cells of the body which helps in avoiding the NK cells activity on normal cells. NK cells have also potent producers of inflammatory cytokines, such as TNF-α and IFN-γ.
""NK Cell Therapies- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the NK Cell Therapies pipeline landscape is provided which includes the disease overview and NK Cell Therapies treatment guidelines. The assessment part of the report embraces, in depth NK Cell Therapies commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, NK Cell Therapies collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the NK Cell Therapies report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
NK Cell Therapies Emerging Drugs
Further product details are provided in the report……..
NK Cell Therapies: Therapeutic Assessment
This segment of the report provides insights about the different NK Cell Therapies drugs segregated based on following parameters that define the scope of the report, such as:
NK Cell Therapies: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses NK Cell Therapies therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging NK Cell Therapies drugs.
NK Cell Therapies Report Insights
Current Treatment Scenario and Emerging Therapies:
Please Note: It will take 3-4 business days to complete the report upon order confirmation.
Geography Covered
- Global coverage
NK Cell Therapies: Overview
Natural killer cells, also known as NK cells are a type of lymphocytes and are key components of the innate immune system. They are highly specific predators that play a major role in the host rejection of both tumors and viral infected cells. NK cells have cytotoxic small granules, which contain special proteins such as perforins and proteases, are known as granzymes in their cytoplasm. Perforins form pores in the cell membrane of the target cell through which the granzymes and associated molecules induce apoptosis. NK cells are derived from the common lymphoid progenitor cells (lymphoblasts), which also generate B and T lymphocytes. They differentiate and mature in the bone marrow, lymph nodes, spleen, tonsils, and thymus, where they then enter into the bloodstream.
NK cells are capable of extravasations and infiltration into tissues and they are activated by interleukins. Natural Killer (NK) cells are capable of secreting cytokines. They act as both cytotoxic effectors and regulators of immune responses and also help in recognizing microbial infection and tumor transformation. They are developed from lymphoid progenitor cells present in the bone marrow. By recognizing self MHC class I molecules, these cells become self-tolerant. After maturation NK cells migrate to lymphoid organs including the liver, uterus, and thymus where they give rise to tissue-specific, functionally distinct mature NK cell subsets.
NK cells act on a large number of receptors that deliver either activating or inhibitory signals. The relative balance of inhibitors and activator signals controls the NK cell activity. NK cell activates post detection of abnormalities in the target cell. It may be due to loss of MHC class I expression or up-regulation of stress-induced ligands that occurs in response to infection or malignant transformation.
NK cells surveillance system includes a number of cell surface activating and inhibitory receptors that control the cytolytic activity of NK cells by sending an either stimulatory or inhibitory signal. The fine balance between activation and inhibition NK cells decides their final action. The inhibitory receptor’s ligands include self-MHC class I molecules that are present on all nucleated cells of the body which helps in avoiding the NK cells activity on normal cells. NK cells have also potent producers of inflammatory cytokines, such as TNF-α and IFN-γ.
""NK Cell Therapies- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the NK Cell Therapies pipeline landscape is provided which includes the disease overview and NK Cell Therapies treatment guidelines. The assessment part of the report embraces, in depth NK Cell Therapies commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, NK Cell Therapies collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence NK Cell Therapies R&D. The therapies under development are focused on novel approaches to treat/improve NK Cell Therapies.
This segment of the NK Cell Therapies report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
NK Cell Therapies Emerging Drugs
- Bemarituzumab: Amgen
- Monalizumab: Innate Pharma
- L1 t-haNK: ImmunityBio
- M ceNK: ImmunityBio
- DF6002: Dragonfly Therapeutics
- oNKord: Glycostem Therapeutics
- KUR-501: Athenex
Further product details are provided in the report……..
NK Cell Therapies: Therapeutic Assessment
This segment of the report provides insights about the different NK Cell Therapies drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in NK Cell Therapies
- There are approx. 140+ key companies which are developing the therapies for NK Cell Therapies. The companies which have their NK Cell Therapies drug candidates in the most advanced stage, i.e. Phase III include, Amgen and Innate Pharma.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
NK Cell Therapies: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses NK Cell Therapies therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging NK Cell Therapies drugs.
NK Cell Therapies Report Insights
- NK Cell Therapies Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing NK Cell Therapies drugs?
- How many NK Cell Therapies drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of NK Cell Therapies?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the NK Cell Therapies therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for NK Cell Therapies and their status?
- What are the key designations that have been granted to the emerging drugs?
- Amgen
- Innate Pharma
- ImmunityBio
- Dragonfly Therapeutics
- Glycostem Therapeutics
- Athenex
- Takeda
- Wugen
- Affimed Therapeutics
- VERAXA
- Asclepius Technology Company Group
- NKGen Biotech
- Sanofi
- Indapta Therapeutics
- Celularity
- GT Biopharma
- Biohaven Pharmaceuticals
- Acepodia
- Allife Medical Science and Technology
- Bright Path Biotherapeutics
- Bemarituzumab
- Monalizumab
- L1 t-haNK
- M ceNK
- DF6002
- oNKord
- KUR-501
- TAK-007
- WU-NK-101
- AFM24
- FLYSYN
- DF1001
- BCMA CAR-NK 92 cells
- SNK01
- SAR445514
- IDP-023
- CYNK-001
- GTB-3550
- BHV-1100
- ACE1702
- Anti-CD19/CD22 CAR NK cell therapy
Please Note: It will take 3-4 business days to complete the report upon order confirmation.
Table of Contents
240 Pages
- Introduction
- Executive Summary
- NK Cell Therapies: Overview
- Introduction
- Mechanism of Action of NK-cells
- NK Cell Activation
- NK Cells in Cancer
- Types of NK-based Immunotherapy
- Genetic modification
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- NK Cell Therapies– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Bemarituzumab: Amgen
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- L1 t-haNK: ImmunityBio
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- KUR-501: Athenex
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- NK Cell Therapies Key Companies
- NK Cell Therapies Key Products
- NK Cell Therapies- Unmet Needs
- NK Cell Therapies- Market Drivers and Barriers
- NK Cell Therapies- Future Perspectives and Conclusion
- NK Cell Therapies Analyst Views
- NK Cell Therapies Key Companies
- Appendix
- *The Table of Contents is not exhaustive; will be provided in the final report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.